Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Two Adjuvant Formulations of an Egg-Derived Pandemic Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* being healthy and ≥ 18 and ≤ 49 years of age~* willing and able to give informed consent~Exclusion Criteria:~* having participated in an influenza H5 vaccine trial in the past~* known to be allergic to any constituent of the vaccine~* serious adverse reactions to previous (influenza) vaccination~* currently participating in another clinical trial or having participated in any clinical trial in the month preceding the start of the study~* using medication that influences the immune system

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None
- 4 (Type: EXPERIMENTAL): None
- 5 (Type: EXPERIMENTAL): None
- 6 (Type: EXPERIMENTAL): None
- 7 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).